Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
Xywav Oral Solution - Reconcile Invoices is a federal award for 260-Network Contract Office 20 (36C260) held by Jazz Pharmaceuticals, Inc. Estimated value $246K ($147K obligated). Current period of performance ends Mar 8, 2025. Last award drew 1 bidder. Place of performance: SAINT LOUIS MO.
Xywav oral solution - reconcile invoices. Latest action is a modification.
Recompete timing
PublicCurrent PoP ended Mar 8, 2025 (592 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 36C26024F0282? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordJazz Pharmaceuticals, Inc — $4.5M obligated across 57 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C26024F0282?
36C26024F0282 (Xywav oral solution - reconcile invoices) is a 260-Network Contract Office 20 (36C260) award with a potential value of $246K, currently held by Jazz Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C260-24-F-0282?
36C260-24-F-0282 is the dashed form of PIID 36C26024F0282 (Xywav oral solution - reconcile invoices), held by Jazz Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C26024F0282?
260-Network Contract Office 20 (36C260) awarded 36C26024F0282 to Jazz Pharmaceuticals, Inc (potential $246K).
Who is the incumbent on 36C26024F0282?
Jazz Pharmaceuticals, Inc is the incumbent with $4.5M across 57 related awards in SCOUT’s public footprint. The current period of performance ends Mar 8, 2025.
When does Jazz Pharmaceuticals, Inc’s 36C26024F0282 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 8, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C26024F0282? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.